DSGN DESIGN THERAPEUTICS INC

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.

The event will be webcast live under the “Events” section of the Investors page of and can also be accessed . A replay of the webcast will be archived on the Design website for 30 days.

Dial-in information for conference participants may be obtained by .

About Design Therapeutics

Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1. Discovery efforts for multiple other serious genetic disorders are also underway. For more information, please visit designtx.com.

Contact:

Investors:

Renee Leck

THRUST Strategic Communications

 



EN
12/03/2024

Underlying

DSGNDESIGN THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DESIGN THERAPEUTICS INC

 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs ...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker Study for DT-168 Initiated in Patients with Fuchs Endothelial Corneal Dystrophy (FECD) Cash and Securities of $216.3 Million Support Continued Pipeline Advancement CARLSBA...

August 7, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosin...

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for s...

June 4, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare...

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. A live webcast of the presentation will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthc...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will ...

May 13, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs ...

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developi...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch